Safety and efficacy on TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Kotani, Daisuke [1 ]
Shitara, Kohei [1 ]
Fukuoka, Shota [1 ]
Bando, Hideaki [1 ]
Okamoto, Wataru [1 ]
Kojima, Takashi [1 ]
Doi, Toshihiko [1 ]
Yoshino, Takayuki [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISS1-1-3
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [41] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
    C. Carriles
    P. Jimenez-Fonseca
    M. Sánchez-Cánovas
    P. Pimentel
    A. Carmona-Bayonas
    T. García
    M. Carbajales-Álvarez
    A. Lozano-Blázquez
    Clinical and Translational Oncology, 2019, 21 : 1781 - 1785
  • [42] Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
    Huemer, Florian
    Piringer, Gudrun
    Schlintl, Verena
    Hackl, Hubert
    Rinnerthaler, Gabriel
    Thaler, Josef
    Greil, Richard
    Weiss, Lukas
    CANCERS, 2020, 12 (10) : 1 - 11
  • [43] Effect of regorafenib and TAS-102 in metastatic colorectal cancer (mCRC) patients on survival in salvage line with different toxicity profile.
    Sugimoto, Naotoshi
    Yoshinami, Tetsuhiro
    Yamamoto, Sachiko
    Yagi, Toshinari
    Imamura, Fumio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [44] The relevance of thymidine kinase 1 (TK1) expression to treatment efficacy of TAS-102 and prognosis in patients (pts) with metastatic colorectal cancer (mCRC)
    Komatsu, Y.
    Yoshino, T.
    Mizunuma, N.
    Yamazaki, K.
    Nishina, T.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S548 - S548
  • [45] A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis
    Yuki, S.
    Komatsu, Y.
    Yagisawa, M.
    Tsuji, Y.
    Harada, K.
    Hatanaka, K.
    Okuda, H.
    Hosokawa, A.
    Ogawa, K.
    Furukawa, K.
    Minami, S.
    Ishiguro, A.
    Honda, T.
    Ohta, T.
    Dazai, M.
    Eto, K.
    Sasaki, T.
    Nakajima, J.
    Sakamoto, N.
    Sakata, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
  • [47] TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Fujita, Naohiro
    Furuta, Takaaki
    Katori, Jun
    Hara, Naoko
    Muro, Kei
    CLINICAL COLORECTAL CANCER, 2016, 15 (04) : E205 - E211
  • [48] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Bendell, Johanna C.
    Rosen, Lee S.
    Mayer, Robert J.
    Goldman, Jonathan W.
    Infante, Jeffrey R.
    Benedetti, Fabio
    Lin, Donghu
    Mizuguchi, Hirokazu
    Zergebel, Christopher
    Patel, Manish R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 925 - 932
  • [49] Analysis retrospective from efficacy with TAS-102 in patients with metastatic colorectal cancer refractory: Experience at two hospitals
    Beatriz, Gonzalez-Astorga
    Cebrian Irene, Gonzalez
    Ma Teresa, Delgado Urena
    Veronica, Conde
    Carmen, Sanchez-Toro
    Javier, Garcia-Garcia
    Encarnacion, Gonzalez-Flores
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis.
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    Berry, Scott R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345